• Odense University Hospital (OUH) plans to deploy three blood drawing devices that aim to increase efficiency, standardization, and patient experience.
• The Odense University Hospital is the first healthcare institution in Denmark to pre-order the innovative blood draw device.
• OUH is expecting delivery in 2025, after Vitestro receives CE approval.
• The pre-order from OUH marks Vitestro’s first international deployment, demonstrating global recognition and trust in the transformative solution.
Illustration of multiple Vitestro blood draw devices with supervisor and patientsDeployment and Vitestro Academy
As the expected CE approval is drawing closer, Vitestro is actively conducting pre-deployment planning with Odense University Hospital. The Vitestro onboarding team will work closely with these partners to ensure smooth delivery, workflow integration, and optimized utilization of the devices in these critical care processes. Customers will engage with the Vitestro Academy program for firsthand device experience before delivery.
Maxine Moor, VP Marketing, Sales, and Customer Success for Europe at Vitestro said:
"As we approach the milestone of CE approval, we are deeply engaged with OUH to facilitating the transition from manual to autonomous blood drawing. Through collaborative deployment discussions and the Vitestro Academy program, we are equipping our partners, like Odense University Hospital with the knowledge and tools needed to seamlessly integrate our innovative devices into their critical care workflows."
On the 22nd of May, Vitestro will be present at the Hospital Automation Summit in Odense, Denmark.
For more information about Vitestro and its innovative blood drawing device, visit
https://vitestro.com.
- END OF NEWS ARTICLE - About Vitestro
Vitestro, an expert in medical robotics, has been developing a device for autonomous blood sampling from patients since 2017. The starting point for the innovation is to create a safe and consistent patient experience in addition to having a positive impact on solving the growing shortage of healthcare personnel. The blood collection device combines AI-driven ultrasound with venipuncture. The procedure is fully automated, from applying the tourniquet to placing a bandage.
With a driven team of over 60 specialists, Vitestro is working on the toughest challenges to achieve the most advanced solutions in our era. Vitestro expects its autonomous blood collection technology to be available in the European market by the end of 2024.
For more information, visit
https://vitestro.com.
For more information, contact:
Vitestro, Utrecht, Nederland
Harm Hoekstra, Marketing and Communication Manager
T: +31 30 200 4551
E:
publicrelations@vitestro.com